We found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitlePhase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.AuthorsAhn MJ; Kim SW; Cho BC; Ahn JS; Lee DH; Sun JM; Massey D; Kim M; Shi Y; Park KPublicationThe oncologist, 2014, Vol 19, Issue 7, p702ISSN1549-490xPublication typearticleDOI10.1634/theoncologist.2013-0419